13F-HR/A filed by Stonepine Capital Management, LLC
Stonepine Capital Management, LLC filed this 13F-HR/A for the quarter ended 2016-06-30, filed 2016-08-11, with 23 holding rows worth $97,537,000.
- Accession
- 0001140361-16-075782
- Filer
- CIK 1440771
- Filed
- 2016-08-11
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q2 2016
A holdings report, amendment of type restatement, 23 entries on the cover page, a total value of $97,537,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $97,537,000 with VALUE read as thousands by filing date, 13F file number 028-17175. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| SCICLONE PHARMACEUTICALS INC | 80862K104 | COM | 1,082,532 | $14,138,000 | thousands by filing date | |
| Viveve Medical, Inc | 092852W20 | COM | 2,599,711 | $10,659,000 | thousands by filing date | |
| AEGERION PHARMACEUTICALS INC | 00767EAB8 | NOTE 2.000 8/1 | 17,300,000 | $9,861,000 | thousands by filing date | principal |
| VANDA PHARMACEUTICALS INC | 921659108 | COM | 811,563 | $9,081,000 | thousands by filing date | |
| TOBIRA THERAPEUTICS INC COM | 88883P101 | COM | 637,567 | $8,008,000 | thousands by filing date | |
| PAIN THERAPEUTICS INC | 69562K100 | COM | 2,837,878 | $6,215,000 | thousands by filing date | |
| QLT INC | 746927102 | COMMON STOCK | 3,779,274 | $5,367,000 | thousands by filing date | |
| SAGENT PHARMACEUTICALS INC | 786692103 | COM | 356,307 | $5,337,000 | thousands by filing date | |
| VERICEL CORP | 92346J108 | COM | 2,250,000 | $5,063,000 | thousands by filing date | |
| CUTERA INC | 232109108 | COM | 438,000 | $4,910,000 | thousands by filing date | |
| SOCIETAL CDMO INC | 75629F109 | COM | 428,670 | $3,408,000 | thousands by filing date | |
| ALERE INC | 01449J105 | COM | 75,000 | $3,126,000 | thousands by filing date | |
| SUCAMPO PHARMACEUTICALS-CL A | 864909106 | CL A | 213,860 | $2,346,000 | thousands by filing date | |
| PACIRA BIOSCIENCES INC COM | 695127100 | Stock | 52,157 | $1,759,000 | thousands by filing date | |
| PERNIX THERAPEUTICS HLDGS IN | 71426VAK4 | DBCV 4.250 4/0 | 6,000,000 | $1,380,000 | thousands by filing date | principal |
| FLAMEL TECHNOLOGIES-SP ADR | 338488109 | SPON | 128,005 | $1,375,000 | thousands by filing date | |
| BIOSPECIFICS TECHNOLOGIES | 090931106 | COM | 30,000 | $1,198,000 | thousands by filing date | |
| Enanta Pharmaceuticals, Inc. | 029251M10 | COM | 52,616 | $1,160,000 | thousands by filing date | |
| DERMA SCIENCES INC | 249827502 | COM PAR $.01 | 283,306 | $1,116,000 | thousands by filing date | |
| VERACYTE INC COM | 92337F107 | Stock | 186,926 | $940,000 | thousands by filing date | |
| CUMBERLAND PHARMACEUTICALS I | 230770109 | COM | 128,798 | $580,000 | thousands by filing date | |
| AVIRAGEN THERAPEUTICS INC | 053761102 | COM | 294,269 | $412,000 | thousands by filing date | |
| DURECT CORP | 266605104 | COM | 80,160 | $98,000 | thousands by filing date |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001140361-16-075518 | superseded | 2016-08-10 | acceptance time not in the bulk data set | |
| 13F-HR/A 0001140361-16-075782 | this filing | 2016-08-11 | acceptance time not in the bulk data set |